NEW YORK, Jan. 22, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of agilon health, inc. (“Agilon Health” or the “Company”) (NYSE: AGL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Agilon Health and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On January 5, 2024, Agilon Health announced revised guidance expectations for 2023 and stated that “[d]uring 2023, agilon health experienced an increase in medical expenses attributable to higher-than-expected specialist visits, Part B drugs, outpatient surgeries, and supplemental benefits, partially offset by lower hospital medical admissions.” In a separate press release, Agilon Health “announced that Timothy Bensley has informed the company of his intent to retire from his position as Chief Financial Officer (CFO) during 2024, which agilon expects to take place within the next nine months.”
On this news, Agilon Health’s stock price fell $3.45 per share, or 28.56%, to close at $8.63 per share on January 5, 2024.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
